Andrew Saik is Chief Financial Officer and Treasurer at Arvinas. Mr. Saik has more than 20 years of biopharma finance experience and has participated in over 40 successful mergers and acquisition transactions. He has been a leader in the strategic transformation of three companies, including executing two inversion transactions that have added billions in value to shareholders.
Prior to joining Arvinas, Mr. Saik served as Chief Financial Officer at Intercept Pharmaceuticals where he led the effort to recapitalize the balance sheet by selling the international division for $450 million and then repurchasing $390 million in convertible debt with a combination of cash and stock. Prior to Intercept Pharmaceuticals, Inc., Mr. Saik was Chief Financial Officer of Vyne Therapeutics, Inc., where he led a buildout of the company’s finance department in the U.S., renegotiated debt obligations to provide the company with enhanced financial flexibility and helped raise over $135 million to fund operations. Prior to joining Vyne Therapeutics, Mr. Saik held CFO positions at PDS Biotechnology, Corp. (formerly Edge Therapeutics), Vertice Pharma, LLC, and Auxilium Pharmaceuticals, Inc. Prior to Auxilium, he was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc., where he helped complete the acquisition of Paladin Labs and restructured $3 billion of debt into a new corporate structure.
Mr. Saik also serves on the board of directors at Milestone Pharmaceuticals.
Mr. Saik received both his Bachelor of Arts in History with an emphasis on business administration, and his Master of Business Administration in Business with an emphasis on finance from the University of Southern California, Los Angeles.
What is Andrew Saik's net worth?
The estimated net worth of Andrew Saik is at least $1.76 million as of May 11th, 2026. Mr. Saik owns 193,128 shares of Arvinas stock worth more than $1,758,237 as of May 22nd. This net worth approximation does not reflect any other investments that Mr. Saik may own. Learn More about Andrew Saik's net worth.
How do I contact Andrew Saik?
Has Andrew Saik been buying or selling shares of Arvinas?
Over the course of the past ninety days, Andrew Saik has sold $110,721.66 in shares of Arvinas stock. Most recently, Andrew Saik sold 11,139 shares of the business's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a transaction totalling $110,721.66. Following the completion of the sale, the chief financial officer now directly owns 193,128 shares of the company's stock, valued at $1,919,692.32. Learn More on Andrew Saik's trading history.
Who are Arvinas' active insiders?
Arvinas' insider roster includes Noah Berkowitz (Chief Medical Officer), Sean Cassidy (CFO), John Houston (CEO), David Loomis (CAO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Andrew Saik (Chief Financial Officer and Treasurer), Timothy Shannon (Director), Ian Taylor (Insider), and Randy Teel (CEO). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?
In the last year, Arvinas insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $495,100.00. In the last year, insiders at the sold shares 14 times. They sold a total of 103,617 shares worth more than $1,184,295.05. The most recent insider tranaction occured on May, 11th when CFO Andrew Saik sold 11,139 shares worth more than $110,721.66. Insiders at Arvinas own 7.3% of the company.
Learn More about insider trades at Arvinas. Information on this page was last updated on 5/11/2026.
